Cargando…

Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure

Objectives: To evaluate the impact of pre- and post-treatment systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) treatment in a cohort of patients with high-grade non-muscle-invasive bladder cancer with bacillus Calmette–Guérin (BCG) failure or intoleranc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiancone, Francesco, Fabiano, Marco, Carrino, Maurizio, Fedelini, Maurizio, Meccariello, Clemente, Fedelini, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Management of NMIBC
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954479/ https://www.ncbi.nlm.nih.gov/pubmed/33763253 http://dx.doi.org/10.1080/2090598X.2021.1874627

Ejemplares similares

Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure
por: Chiancone, Francesco, et al.
Publicado: (2020)

Assessment of the oncological outcomes of three different bacillus Calmette–Guérin strains in patients with high-grade T1 non-muscle-invasive bladder cancer
por: Nowak, Łukasz, et al.
Publicado: (2021)

Preliminary evidence of the impact of social distancing on psychological status and functional outcomes of patients who underwent robot-assisted radical prostatectomy
por: Chiancone, Francesco, et al.
Publicado: (2020)

The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status
por: Nowak, Łukasz, et al.
Publicado: (2020)

Laparoscopic management of recurrent ureteropelvic junction obstruction following pyeloplasty: a single surgical team experience with 38 cases
por: Chiancone, Francesco, et al.
Publicado: (2017)

Comparison of laparoscopic versus open simple nephrectomy in patients with xanthogranulomatous pyelonephritis: A singlecenter analysis of outcomes and predictors of surgical approaches and complications
por: Chiancone, Francesco, et al.
Publicado: (2023)

The increased risk of complicated ureteral stones during COVID-19 pandemic: a single-institution experience
por: Chiancone, F., et al.
Publicado: (2021)

Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients
por: Carando, Roberto, et al.
Publicado: (2020)

Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: The HIVEC-II trial
por: Bhargava, Priyank
Publicado: (2023)

Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
por: Anastay, Vassili, et al.
Publicado: (2023)

A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer
por: Van Hattum, J. W., et al.
Publicado: (2022)

Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette–Guérin for Treatment of Bladder Cancer
por: Branco, Elsa Alves, et al.
Publicado: (2021)

Managing the adverse events of intravesical bacillus Calmette–Guérin therapy
por: Decaestecker, Karel, et al.
Publicado: (2015)

Tuberculous Spondylitis Caused by Intravesical Bacillus Calmette-Guerin Therapy
por: Minakata, Tomokazu, et al.
Publicado: (2020)

Reactive Arthritis After Intravesical Bacillus Calmette-Guérin Therapy
por: Taniguchi, Yoshinori, et al.
Publicado: (2022)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Guérin therapy
por: Obaid, Sami, et al.
Publicado: (2011)

Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019)

Disseminated Granulomatous Disease from Intravesical Instillation of Bacillus Calmette-Guerin
por: Ghafouri, Sayed Ab. Reshad, et al.
Publicado: (2018)

Tuberculosis epididymo-orchitis following intravesical bacillus Calmette-Guérin immunotherapy
por: Rezvani, Sean, et al.
Publicado: (2019)

Miliary Tuberculosis that Developed after Intravesical Bacillus Calmette-Guerin Therapy
por: Kaburaki, Kyohei, et al.
Publicado: (2017)

Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer
por: Miyazaki, Masashi, et al.
Publicado: (2016)

Tuberculous prostatic abscess following intravesical bacillus Calmette-Guérin immunotherapy
por: Wang, Bin, et al.
Publicado: (2019)

Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
por: Guerrero-Ramos, Félix, et al.
Publicado: (2022)

Pityriasis Rosea-Like Rash Secondary to Intravesical Bacillus Calmette-Guerin Immunotherapy
por: Oh, Chee Won, et al.
Publicado: (2012)

Case report: Mycobacterium bovis orchitis post intravesical Bacillus Calmette Guerin
por: Samannodi, Mohammed, et al.
Publicado: (2018)

Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guèrin Therapy
por: Nagai, Takashi, et al.
Publicado: (2019)

A severe complication of intravesical bacillus Calmette-Guerin: An effect of different strains
por: Low, Li Sian, et al.
Publicado: (2021)

Penile lesion with inguinal adenopathy after intravesical Bacillus Calmette-Guerin instillation therapy
por: Aslan, Guven, et al.
Publicado: (2013)

Intravesical bacillus Calmette-Guerin for bladder cancer: What is known? What is not? What is next?
por: Madbouly, Khaled
Publicado: (2013)

Tuberculous Prostatic Abscess with Prostatorectal Fistula after Intravesical Bacillus Calmette-Guérin Immunotherapy
por: Eom, Jeong Ho, et al.
Publicado: (2016)

Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer
por: Liu, Yuqing, et al.
Publicado: (2019)

Henoch Schönlein Purpura Nephritis Associated with Intravesical Bacillus Calmette-Guerin (BCG) Therapy
por: Tsukada, Hiroyuki, et al.
Publicado: (2017)

Hepatic Injury without Granulomatous Formation Associated with Intravesical Bacillus Calmette-Guérin Therapy
por: Okano, Hiroshi, et al.
Publicado: (2019)

Mycobacterium Bovis Spondylodiscitis: A Rare Complication of Intravesical Bacillus Calmette-Guérin Therapy
por: Quatannens, Frédéric, et al.
Publicado: (2022)

Bacillus Calmette-Guérin Spondylodiscitis after Intravesical BCG Therapy: A Case Report
por: Kawai, Akihito, et al.
Publicado: (2022)

Intravesical bacillus Calmette–Guérin-induced myopathy presenting as rhabdomyolysis: a case report
por: Lee, Chae Hun, et al.
Publicado: (2023)

Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
por: Garcia, Cindy, et al.
Publicado: (2015)

Poncet’s disease after the intravesical instillation of Bacillus Calmette–Guérin (BCG): a case report
por: Sampaio, Paula Cíntia Machado, et al.
Publicado: (2017)

Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c9e473qinuj4vti5jbcr411m2l